This Pet Health Company Sees Growing Demand For Farm-Animal Products, Cost Savings From Restructuring
Portfolio Pulse from Vandana Singh
Elanco Animal Health Inc (NYSE:ELAN) reported Q4 2023 revenue of $1.035 billion, a 5% increase, surpassing consensus estimates. Adjusted EPS was $0.08, missing expectations and down 59% Y/Y. Pet Health revenue declined by 1%, while Farm Animal revenue grew by 10%. The company announced a restructuring impacting 420 personnel, aiming for annualized savings. FY 2024 sales are forecasted between $4.45 billion and $4.54 billion, with adjusted EPS of $0.87-$0.95. ELAN shares dropped 0.58% to $16.28.
February 26, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Elanco Animal Health Inc reported higher than expected Q4 2023 revenue but missed EPS estimates. The company sees a mixed performance across segments and announced a restructuring plan.
The mixed earnings report, with a revenue beat but an EPS miss, and the announcement of a restructuring plan impacting 420 personnel, could lead to short-term negative sentiment among investors. The decline in share price following the report indicates immediate market reaction.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100